Abstract
Despite advances in oncology therapeutics and biomedical research that have transformed since the turn of this century and deepened our understanding of cancer hallmarks, resulting in the discovery and development of targeted therapies, the success rates of oncology drug development remain low. Opportunities have increased with the understanding of molecular basis of the cancer translating to the discovery, development and availability of targeted therapies that have brought meaningful benefit
to patients with diverse malignancies.One of the most challenging aspects of head and neck oncology is the selection of the most appropriate treatment for an individual patient with squamous cell carcinoma. The encouraging results from neoadjuvant chemotherapy and radiotherapy for patients with larger tumours, call for the identification of new accurate predictors of response to radiotherapy so that the appropriate therapy can be tailored better for individual patients.
Keywords
References
Bucci MK, Bevan A, Roach M 3rd. Advances in radiation therapy: conventional to 3D, to IMRT, to 4D, and beyond. CA Cancer JClin. 2005;55:117–34.
Chapman JD. Single-hit mechanism of tumour cell killing by radiation. Int J Radiat Biol. 2003;79(2):71–81.
Sinclair WK, Morton RA. Variations in X-ray response during the division cycle of partially synchronized Chinese hamster cells in culture. Nature. 1963;199:1158–60.
Vikram B, Strong EW, Shah JP, Spiro R. Failure in the neck following multimodality treatment for advanced head and neck cancer. Head Neck Surg. 1984;6(3):724–29.
Bristow RG, Benchimol S, Hill RP. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. Radiother Oncol. 1996;40:197–223.
Littbrand B, Révész L. The effect of oxygen on cellular survival and recovery after radiation. Br J Radiol. 1969;42(504):914–24.
Martin L, Green B, Renshaw C, Lowe D, Rudland P, Leinster SJ. Examining the technique of angiogenesis assessment in invasive breast cancer. Br J Cancer. 1997;76(8):1046–54.
Brun E, Zätterström U, Kjellén E, Zatterstrom U, Kjellen E, Wahlberg P, et al. Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas. Acta Oncol. 2001;40:491–6.
Shintani S, Kiyota A, Mihara M, Nakahara Y, Terakado N, Ueyama Y, et al. Association of preoperative radiation effect with tumour angiogenesis and vascular endothelial growth factor in oral squamous cell carcinoma. Jpn J Cancer Res. 2000;91(10):1051–7.
Aebersold DM, Beer KT, Laissue J, Hug S, Kollar A, Greiner RH, et al. Intratumoral microvessel density predicts local treatment failure of radically irradiated squamous cell cancer of the oropharynx. Int J Radiat Onocol Biol Phys. 2000;48:17–25.
Rosen EM, Fan S, Goldberg ID, Rockwell S. Biological basis of radiation sensitivity. Part 2: cellular and molecular determinants of radiosensitivity. Oncology (Williston Park). 2000;14(5):741–57; discussion 757–8.
Jayasurya R, Francis G, Kannan S, Lekshminarayanan K, Nalinakumari KR, Abraham T, et al. p53, p16 and cyclin D1: molecular determinants of response to radiotherapy treatment response in oral carcinoma. Int J Cancer. 2004;109(5):710–6.
Jeggo PA, Taccioli GE, Jackson SP. Menage à trios: double strand break repair, V(D)J recombination and DNA-PK. Bioassays. 1995;17(11):949–57.
Gottlieb TM, Jackson S. The DNA-dependent protein kinase:requirement for DNA ends and association with Ku antigen. Cell. 1993;72(1):131–42.
Shintani S, Mihara M, Li C, Nakahara Y, Hino S, Nakashiro K, et al. Up-regulation of DNA-dependent protein kinase correlates with radiation resistance in oral squamous cell carcinoma. Cancer Sci. 2003;94(10):894–900.
Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications.Lancet Oncol. 2001;2(11):667–73.
Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev. 1992;13(1):18–32.
Ferrara N. Vascular endothelial growth factor as a target for anticancer therapy. Oncologist. 2004;9(Suppl 1):2–10.
Harari PM, Huang SM. Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation. Int J Radiat Onocol Biol Phys. 2001;49(2):427–33.
Smith BD, Smith GL, Carter D, Sasaki CT, Haffty BG. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol. 2000;18(10):2046–52.
Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ, Boyle JO. Cyclooxygenase- 2: a novel molecular target for the prevention and treatment of head and neck cancer. Head Neck. 2002;24:792–9.
Terakado N, Shintani S, Yano J, Chunnan L, Mihara M, Nakashiro K, Hamakawa H. Overexpression of cyclooxygenase-2 is associated with radioresistance in oral squamous cell carcinoma. Oral Oncol. 2004;40(4):383–9.
Nikitakis NG, Sauk JJ, Papanicolaou SI. The role of apoptosis in oral diseases: mechanisms; aberrations in neoplastic, autoimmune; infectious; hematologic and developmental
diseases; and therapeutic options. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;97(4):476–90.
Loro LL, Vintermyr OK, Liavaag PG, Johannessen AC. Oral squamous cell carcinoma is associated with decreased bcl-2/bax expressed ratio and increased apoptosis. Hum Pathol. 1999;30(9):1097–105.
Xie X, Clausen OP, Boysen M. Prognostic value of Bak expression in oral tongue squamous cell carcinomas. Oncol Rep. 2003;10(2):369–74.
Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis, Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer. 1999;86(6):913–20.
Vora HH, Shah NG, Patel DD, Trivedi TI, Chikhlikar PR. Prognostic significance of biomarkers in squamous cell carcinoma of the tongue: multivariate analysis. J Surg Oncol. 2003;82(1):34–50.
Harari PM. Epidermal growth factor receptor inhibition strategies in oncology. Endocr Relat Cancer. 2004;11(4):689–708.
Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001;37(Suppl 4):S3–S8.
Song JI, Grandis JR. STAT signaling in head and neck cancer. Oncogene. 2000;19(21):2489–95.
Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59(8):1935–40.
Gee JM, Nicholson RI. Expanding the therapeutic repertoire of epidermal growth factor receptor blockade: radiosensitization. Breast Cancer Res. 2003;5(3):126–9.
Tamatani T, Azuma M, Ashida Y, Motegi K, Takashima R, et al. Enhanced radiosensitization in NF-kappaB-suppressed human oral cancer cells via the inhibition of gamma-irradiationand 5-FU-induced production of IL-6 and IL-8. Int J Cancer.2004;108(6):912–21.
Baselga J. The EGFR as a target for anticancer therapy—focus on cetuximab. Eur J Cancer. 2001;37(Suppl 4):S16–S22.
Refbacks
- There are currently no refbacks.
Copyright (c) 2016 Journal of Pharmaceutical and Biomedical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.